Aug 22, 2024 / 12:00PM GMT
Jens Lindberg - Medivir AB - Chief Executive Officer
Thank you very much and a warm welcome, everyone to the quarter two results webcast here at Medivir. I hope everyone has had a great summer as we sort of kick off again, after a warm and long summer vacation.
Here at Medivir of you, we closed out quarter two sort of at the beginning of the summer on a very high note when we presented sort of a strong data set for the first structure, Lenvima combination at ESMO GI Congress in Munich, and we will come back to that and share a bit more details today in terms of the data presented. And how we are now working forward with the Fostrox development program.
So important information which you will find as you access the presentation on the website. As mentioned in quarter two we were able to share a very exciting data set at ESMO GI, where we can see or could see for the Fostrox Lenvima combination, a superior efficacy compared with what has been shown in previous published studies in the second-line liver cancer space.
Equally important, we could confirm in that data set, and
Q2 2024 Medivir AB Earnings Call Transcript
Aug 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers